
TME PHARMA announces publication of abstract disclosing positive interim results from Bevacizumab expansion arm of NOX-A12 GLORIA phase 1/2 brain cancer clinical trial
. Data show 83% of chemotherapy refractory patients achieved radiographic partial response All radiographic partial re…